TrialCPT: pharmacometrics & systems pharmacology2026

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.

Heiko Babel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.